Statins 'don't work well for one in two people'
Fresh research questions the merit of the cholesterol-lowering pills taken by millions of Britons.
In patients with type 2 diabetes and hyperlipidemia or mixed dyslipidemia on a maximally tolerated statin, treatment with evolocumab lowers low-density-lipoprotein cholesterol (LDL-C) and improves levels of other lipids, researchers say.Reuters Health Information
Like more than half of older men, I take a cholesterol-lowering medication called a statin. Sometimes that seems a bit strange, because I don ’t have high cholesterol. My doctor prescribed it based on a formula that largely hinges on age and sex. I’m 71 and male. Those two factors alone put me in the high-risk category for […]Find jobs at Careers by KevinMD.com. Search thousands of physician, PA, NP, and CRNA jobs now. Learn more.
Authors: Simons LA Abstract Statin drugs reduce low-density lipoprotein (LDL)-cholesterol (LDL-C) and cardiovascular risk. Ezetimibe may be used to supplement statin therapy, or used alone in cases of statin intolerance. Statin-associated side effects do occur, especially muscle symptoms and new onset diabetes, but they do not detract from the benefits of statin therapy. Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce LDL-C and cardiovascular risk. Evolocumab is subsidised in Australia for patients with familial hypercholesterolaemia when LDL-C is not adequately controlled with maximum do...
This study aimed to evaluate the association between the duration and recent use of statin, and the risk of NODM...
AbstractIntroductionBased on the observation of beneficial effects on cancer metabolism, microenvironment, or VEGF-signaling, several non-anticancer drugs have been discussed as useful in renal cell carcinoma (RCC). In the present study, we investigated the prognostic impact of concomitant medication in RCC and correlated comedication with cell-cycle and proliferation activity in corresponding surgical specimen.MethodsA total of 388 patients who underwent surgery for localized RCC were included. The individual medication was evaluated according to substance classes. Tissue microarrays from corresponding tumor specimen were...
ConclusionvlCRP is associated with younger age, non-smoking, and absence of hyperlipidemia and of hypertension. However, it may also be part of the individual physiology.
Headlines last week declaring that statins ‘do not work’ in half of patients will have made intriguing reading – for the eight million Britons taking them, and for anyone else considering doing so.
Publication date: May 2019Source: American Journal of Kidney Diseases, Volume 73, Issue 5Author(s):
Authors: Heijnen NFL, Bergmans DCJJ, Schnabel RM, Bos LDJ PMID: 30997202 [PubMed]